SFOSF
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Set alert
2.18 USD 0.00 0.00%
2.20 Day range 2.20
1.93 52-week range 3.30
- YTD
- -13.00%
- 1 year
- -34.09%
- Open
- 2.20
- Prev close
- 2.18
- Mkt cap
- 8.18B
- Vol
- 100
- Avg vol
- 110
- EPS
- 0.19
- P/E
- 11.45
More statistics
- Low
- 2.20
- High
- 2.20
- Earnings
- Aug 26, 2026
Next earnings
Aug 26, 2026
Expected Aug 26, 2026. Consensus EPS estimate 0.04162.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 26, 2026 | Dec 31, 2025 | 0.04162 | — | — | — |
| Apr 27, 2026 | Mar 31, 2026 | — | 0.04795 | — | — |
| Aug 26, 2025 | Jun 30, 2025 | — | 0.04907 | — | — |
| Apr 29, 2025 | Mar 31, 2025 | — | 0.03944 | — | — |
| Mar 25, 2025 | Dec 31, 2024 | — | 0.03904 | — | — |
News
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Q2 2026 Earnings Call Transcript
- Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (OTCMKTS:SFOSF) Short Interest Up 21.2% in January
- Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
- Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech
- Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal
- Pandemic Accelerates China's Drive Into mRNA Treatments
- Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
- Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
Your note
Sign in to keep a note on SFOSF — it syncs with the Stock Master app.